Summit Trail Advisors LLC Invests $1.89 Million in Krystal Biotech, Inc. (NASDAQ:KRYS)

Summit Trail Advisors LLC acquired a new stake in Krystal Biotech, Inc. (NASDAQ:KRYS) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 10,401 shares of the company’s stock, valued at approximately $1,893,000.

A number of other institutional investors have also recently made changes to their positions in KRYS. GAMMA Investing LLC raised its stake in Krystal Biotech by 160.3% in the second quarter. GAMMA Investing LLC now owns 151 shares of the company’s stock valued at $28,000 after purchasing an additional 93 shares in the last quarter. Jamison Private Wealth Management Inc. bought a new stake in shares of Krystal Biotech during the 2nd quarter valued at about $28,000. Key Financial Inc purchased a new position in shares of Krystal Biotech during the 2nd quarter worth approximately $28,000. Blue Trust Inc. boosted its position in shares of Krystal Biotech by 2,328.6% during the second quarter. Blue Trust Inc. now owns 170 shares of the company’s stock valued at $30,000 after purchasing an additional 163 shares in the last quarter. Finally, Values First Advisors Inc. bought a new position in Krystal Biotech in the third quarter worth $53,000. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Insider Buying and Selling at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the sale, the insider now directly owns 1,500,882 shares in the company, valued at $296,814,424.32. The trade was a 1.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 14.10% of the stock is owned by insiders.

Analyst Ratings Changes

A number of equities research analysts have recently commented on KRYS shares. Citigroup increased their price target on shares of Krystal Biotech from $204.00 to $206.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Stifel Nicolaus lifted their price objective on shares of Krystal Biotech from $204.00 to $220.00 and gave the stock a “buy” rating in a research note on Wednesday, September 11th. HC Wainwright reaffirmed a “buy” rating and issued a $221.00 price objective on shares of Krystal Biotech in a research report on Tuesday, November 5th. William Blair raised Krystal Biotech to a “strong-buy” rating in a research report on Friday, August 30th. Finally, Chardan Capital upped their price target on shares of Krystal Biotech from $153.00 to $208.00 and gave the company a “buy” rating in a research note on Monday, August 5th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $202.29.

Krystal Biotech Stock Performance

Shares of KRYS opened at $190.40 on Monday. Krystal Biotech, Inc. has a 1 year low of $99.00 and a 1 year high of $219.34. The company’s fifty day moving average is $179.54 and its two-hundred day moving average is $182.54. The stock has a market capitalization of $5.48 billion, a P/E ratio of 107.57 and a beta of 0.82.

Krystal Biotech (NASDAQ:KRYS) last announced its earnings results on Monday, November 4th. The company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.84 by $0.07. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The firm had revenue of $83.84 million during the quarter, compared to the consensus estimate of $82.94 million. During the same quarter in the previous year, the company posted ($0.67) EPS. The firm’s revenue for the quarter was up 879.9% on a year-over-year basis. Sell-side analysts predict that Krystal Biotech, Inc. will post 2.97 EPS for the current year.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).